MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) rose 5.8% on Tuesday . The company traded as high as $9.13 and last traded at $9.21. Approximately 82,488 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 636,250 shares. The stock had previously closed at $8.71.
Analyst Upgrades and Downgrades
Separately, StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $12.00.
Read Our Latest Stock Analysis on MDXG
MiMedx Group Stock Down 2.1 %
The firm has a fifty day moving average price of $9.19 and a 200 day moving average price of $7.52. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of 15.84 and a beta of 1.96. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.02. The business had revenue of $84.06 million during the quarter, compared to the consensus estimate of $81.00 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. During the same quarter last year, the firm posted $0.05 EPS. As a group, sell-side analysts expect that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.
Institutional Investors Weigh In On MiMedx Group
A number of large investors have recently added to or reduced their stakes in MDXG. Blue Trust Inc. purchased a new stake in shares of MiMedx Group in the third quarter valued at $30,000. Point72 Asset Management L.P. acquired a new stake in shares of MiMedx Group during the second quarter worth $40,000. Van ECK Associates Corp purchased a new stake in shares of MiMedx Group in the fourth quarter valued at $40,000. Point72 DIFC Ltd lifted its position in MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock worth $45,000 after buying an additional 4,275 shares during the period. Finally, Entropy Technologies LP acquired a new position in shares of MiMedx Group in the 3rd quarter valued at $64,000. 79.15% of the stock is owned by institutional investors and hedge funds.
About MiMedx Group
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Further Reading
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
